Navigation Links
Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
Date:9/28/2010

WORCESTER, Mass., Sept. 28 /PRNewswire/ -- Generex Biotechnology Corporation (Nasdaq: GNBT, www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has been awarded a new patent in Canada.

The Canadian Intellectual Property Office granted Canadian Patent No. 2,401,942, a patent titled "Pharmaceutical Compositions for Buccal and Pulmonary Application".

This new patent increases the number of issued patents related to the Company's buccal drug delivery platform technologies to 161.  A total of 102 patent applications remain pending.

"We are pleased that we continue to establish the inventiveness of the Company's buccal delivery system as there has been relatively little progress over the years in reaching the target of safe and effective oral formulations for macromolecules, including peptides and proteins", stated Rose C. Perri, the Company's Chief Operating Officer.  "We are pleased that we continue to receive patents from key markets within which our delivery system can be commercialized with a pipeline of viable applications that will open up other marketplaces for the Company".  

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's flagship product, oral insulin (Generex Oral-lyn™), which has been launched in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials.  Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


'/>"/>
SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Generex Presents Abstract at EASD Annual Meeting
2. Generex Announces Sales Agreement with Elias Shaker & Company
3. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
4. Generex Announces Presentations of Novel Vaccine Strategies
5. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
6. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
7. Microfluidic Systems (MFSI) is Awarded Four New Patents in the Field of Automated Biological Sample Processing and Detection.
8. WuXi PharmaTech Awarded GLP Certificate from OECD for Suzhou Toxicology Facility
9. Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics
10. Sysmex America Awarded National Novation GPO Contract for Automated Urinalysis
11. Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... , Jan. 14, 2017  Johnson & Weaver, LLP ... of purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ... through October 31, 2016 (the "Class Period"). Zimmer ... and markets orthopaedic reconstructive products, such as knee and hip ... ...
(Date:1/13/2017)... Eli Lilly and Company (NYSE: ... ) announced today that the U.S. Food and Drug ... new drug application (NDA) for investigational baricitinib, a once-daily ... rheumatoid arthritis (RA). The NDA for baricitinib was submitted ... FDA extended the action date to allow time to ...
(Date:1/13/2017)... New York , January 13, 2017 ... rising prevalence of AIDS will collectively contribute to the demand ... expected to reach a value of US$ 551.0 Mn by ... will remain the most lucrative markets for western blotting, ... lead the market globally. ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Houston ... Center, is currently offering complimentary consultations and financing for orthodontics for a limited ... bite irregularities and learn about their orthodontic options. Walk-in, late-evening, Saturday, and same-day ...
(Date:1/16/2017)... MO (PRWEB) , ... January 16, 2017 , ... St. Louisans are well-aware of the ... , This year’s influenza shot seems to be having no effect on keeping ... at least half of the people around are coughing, sneezing, or sniffling ...
(Date:1/16/2017)... ... , ... San Francisco dentist, Dr. Ben Amini , the founder at ... is capable of taking digital impressions of teeth and gums. Conventional bite impressions have ... restorations , in terms of speed, efficiency and patient comfort. Increasingly, digital impressions are ...
(Date:1/15/2017)... ... 15, 2017 , ... Whole Health Supply, LLC is announcing the release of an updated version ... for purchase. , The 2017 edition has wide jaws that will accommodate nails up ... as well as diabetics. This handle is reinforced for extra strength when pressing down on ...
(Date:1/15/2017)... ... January 15, 2017 , ... The Gravity Vault Indoor Rock Climbing Gym is ... wraps up on the 14,000+ square foot climbing gym, the owners anticipate to open ... in New Jersey and two in New York. With this being its first location ...
Breaking Medicine News(10 mins):